IN2014CN02959A - - Google Patents

Info

Publication number
IN2014CN02959A
IN2014CN02959A IN2959CHN2014A IN2014CN02959A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A IN 2959CHN2014 A IN2959CHN2014 A IN 2959CHN2014A IN 2014CN02959 A IN2014CN02959 A IN 2014CN02959A
Authority
IN
India
Prior art keywords
compounds
formula
abvdisclosed
het
salts
Prior art date
Application number
Other languages
English (en)
Inventor
Mark E Layton
Joseph E Pero
Hannah Fiji
Michael J Kelly Iii
Leon Pablo De
Michael A Rossi
Kevin F Gilbert
Anthony J Roecker
Zhijian Zhao
Swati Pal Mercer
Scott Wolkenberg
James Mulhearn
Lianyun Zhao
Dansu Li
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN02959A publication Critical patent/IN2014CN02959A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
IN2959CHN2014 2011-10-28 2012-10-26 IN2014CN02959A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552885P 2011-10-28 2011-10-28
PCT/US2012/062207 WO2013063459A1 (en) 2011-10-28 2012-10-26 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels

Publications (1)

Publication Number Publication Date
IN2014CN02959A true IN2014CN02959A (zh) 2015-07-03

Family

ID=48168585

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2959CHN2014 IN2014CN02959A (zh) 2011-10-28 2012-10-26

Country Status (12)

Country Link
US (1) US9273040B2 (zh)
EP (1) EP2770995B1 (zh)
JP (1) JP2014532660A (zh)
KR (1) KR20140095067A (zh)
CN (1) CN103889419A (zh)
AU (1) AU2012328561A1 (zh)
BR (1) BR112014010197A2 (zh)
CA (1) CA2852796A1 (zh)
IN (1) IN2014CN02959A (zh)
MX (1) MX2014005068A (zh)
RU (1) RU2014121489A (zh)
WO (1) WO2013063459A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
AU2015242219A1 (en) 2014-03-29 2016-10-06 Lupin Limited Sulfonamide compounds as Voltage gated sodium channel modulators
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
CR20170392A (es) * 2015-03-02 2018-02-20 Amgen Inc Compuestos bicíclicos de sulfonamida cetona
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CA3008611A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201809702SA (en) 2016-05-20 2018-12-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CA3039853A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
SG10201912372XA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AR112187A1 (es) * 2017-05-11 2019-10-02 Glaxosmithkline Ip Dev Ltd Compuesto de 2-oxo-benzo[d]oxazol-6-sulfonamida, composición farmaceutica que lo comprende y su uso para la fabricación de un medicamento
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019204740A1 (en) * 2018-04-19 2019-10-24 University Of Virginia Patent Foundation Compositions and methods for preparing and using azetidines
PE20211389A1 (es) 2018-06-13 2021-07-27 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos
JP7383012B2 (ja) 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
PE20211066A1 (es) 2018-08-31 2021-06-09 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
EP1144387A1 (en) * 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
EP1918279A3 (en) * 2001-04-18 2008-07-16 Euro-Celtique S.A. 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (orl1) ligands for the treatment of pain
US7408067B2 (en) * 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
WO2006133459A1 (en) * 2005-06-09 2006-12-14 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels
CA2633653A1 (en) * 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
CA2693588C (en) * 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
EP2330899A1 (en) * 2008-08-21 2011-06-15 Richter Gedeon Nyrt. Methods for treating neuropathic pain
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
PL2427441T3 (pl) * 2009-05-04 2017-06-30 Agios Pharmaceuticals, Inc. Aktywatory PKM2 do stosowania w leczeniu raka

Also Published As

Publication number Publication date
AU2012328561A1 (en) 2014-04-17
CA2852796A1 (en) 2013-05-02
RU2014121489A (ru) 2015-12-10
JP2014532660A (ja) 2014-12-08
EP2770995B1 (en) 2019-01-02
CN103889419A (zh) 2014-06-25
US20140303143A1 (en) 2014-10-09
EP2770995A1 (en) 2014-09-03
BR112014010197A2 (pt) 2017-04-18
WO2013063459A1 (en) 2013-05-02
US9273040B2 (en) 2016-03-01
EP2770995A4 (en) 2015-06-03
AU2012328561A8 (en) 2014-05-01
KR20140095067A (ko) 2014-07-31
MX2014005068A (es) 2014-07-30

Similar Documents

Publication Publication Date Title
IN2014CN02959A (zh)
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018501288A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
BR112015009216A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
CL2015001599A1 (es) Compuestos derivados de (piridin o pirimidin)-(piperidina o piperazina) sustituidos o sus sales, inhibidores de la colesterol 24-hidroxilasa (ch24h); medicamento; metodo de inhibicion de la ch24h; metodo para prevenir o tratar; y uso para la prevencion o tratamiento de epilepsia, alzheimer y parkinson, entre otras enfermedades.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2015009591A (es) Amidas como moduladores de canales de sodio.
PT2822555T (pt) Inibição da cinase 1 associada a adaptador para o tratamento da dor
PH12015502365A1 (en) Bace1 inhibitors
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
WO2013040227A3 (en) Therapeutic compounds
NZ738672A (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
TN2015000275A1 (fr) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
IN2012DN06061A (zh)
WO2013148638A3 (en) Compositions and methods related to inhibitors of jak kinase
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
WO2013121334A3 (en) Agents for treating neurodegenerative disorders
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders